Table 2.
Significant CpG sites and probes associated with a disease group (FDR < 0.05) in the individual-level analyses
| Analysis | Probe/CpG | Coef | SE | P value | FDR | Gene |
|---|---|---|---|---|---|---|
| EWAS of prevalent cerebrovascular diseases | cg16541931 | 0.14 | 0.03 | 3.48E−8 | 0.0079 | GPR158;GPR158-AS1 |
| cg09378783 | − 0.26 | 0.05 | 2.32E−8 | 0.0079 | EGFR | |
| cg04329510 | − 0.17 | 0.03 | 1.58E−7 | 0.0238 | C5AR1 | |
| EWAS of incident coronary artery diseases | cg06567227 | − 1.28 | 0.21 | 6.64E−8 | 0.03 | SIM1 |
| cg06714480 | 2.05 | 0.35 | 1.33E−7 | 0.03 | CERKL;NEUROD1 | |
| TWAS of prevalent diseases of the veins and lymphatic system | A_19_P00806441 | − 0.07 | 0.01 | 9.32E−8 | 0.0032 | LOC105370365 |
Coef.; coefficient, SE; standard error, FDR: false discovery rate, EWAS: epigenome-wide association study, TWAS: transcriptome-wide association study